TIDMOPTI
RNS Number : 4760S
OptiBiotix Health PLC
17 March 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Commercial strategy update
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, provides an update on the progress of
its commercial strategy.
The strategy is designed to build brand presence and early sales
of OptiBiotix's first generation functional ingredients LP(LDL)
(R), SlimBiome(R), and WellBiome(R) and establish a global network
of partners. This provides the base of a sustainable business with
the probiotic and functional fibre divisions achieving
profitability in 2020. Now this has been achieved, the next phase
of the strategy is to scale the commercially established first
generation product sales by extending product lines and territories
with existing partners, and grow profitability by moving up the
value chain to sell more product than ingredients. This increases
revenues and margin and has a compounding revenue effect in pulling
through ingredients sales. This will be accompanied by a focus on
commercialising next generation products including the microbiome
modulators, LP(LDL) (R) as a drug biotherapeutic, and the growing
suite of SweetBiotix(R) products.
This Company update is intended to report progress against that
strategy:
1. Extension of product range with Holland and Barrett
("H&B") : H&B have launched an extended range of products
under their own in-house SlimExpert brand in addition to
SlimBiome(R) shots. This extends the number of products containing
SlimBiome(R) from three to eight, more than doubling H&B's
product offering. The new product range comprises three flavours of
meal replacements and two porridge flavours and are a direct result
of H&B tasting and testing OptiBiotix's finished product
applications available from its online store. The doubling of a
product offering and creation of H&B's new own brand range is a
big commitment to SlimBiome(R) by a major retailer.
2. Launch of SlimBiome and OptiBiome products in Asia: Primo
trading have launched a range of products called Prym Fiber through
Amata Life Plus in Thailand. This follows on from the launch of a
slimming green tea (OB-EX) containing SlimBiome through the same
partner. In addition, Maxcare Inc, have launched a mixed berry
flavour SlimBiome jelly stick in Taiwan through a major online TV
shopping channel. The launch of products in the region is intended
to increase market awareness of the Company's functional ingredient
brands in Asia as a forerunner to launching finished products in
the larger Asian markets like Singapore and China. OptiBiotix has a
distribution agreement with United Italian Trading Corporation
(Pte) Ltd for CholBiome(R)(X3) and SlimBiome(R) Medical and
anticipates launches of these products in Singapore in early Q2
2021 and China contributing revenues this fiscal year.
3. Agreements to distribute final products in Africa: OptiBiotix
has signed agreements with Dipromed, a distributor of food
supplements and medical devices, for the sale of SlimBiome(R)
Medical and CholBiome(R) products in Morocco and Algeria. Revenue
generation is anticipated in 2021 dependent on registration of the
products in the territories.
4. Extension of SlimBiome in India: Anthem Biosciences have
extended their existing product range of Metalite pro in India and
Zeon Lifesciences have launched the ZeoSlim range of meal
replacements in India. Dr Taru joins the team on 17 March to build
on these early successes and grow sales in the strategically
important Indian and Asian markets. Given the size of this market
and the scale of the partners the Company are in discussions with,
the team anticipate India making a substantial contribution to
sales growth in the future.
5. USA product launch: The Company has launched the Dietworks
Appetite control gummies in the USA. Dietworks is a specialised US
weight management company which sells products through online and
retail channel across the USA. This is another point of access to
the large US market.
6. Actial Farmaceutica Srl: Due to a high level of customer
interest, Actial Farmaceutica Srl ("Actial"), owner of one of the
world's best known probiotic brand called VSL(#) 3(R), have
requested and been granted an extension to distribute CholBiome(R)
and CholBiome(R)(X3) under the VSL#Cardio(R) range to two new
territories (France and Malaysia) in addition to the existing
territories (Australia, New Zealand, Indonesia and Thailand).
Actial sell clinically proven products into the high value pharma,
GP, and hospital networks. It is anticipated that an ongoing roll
out of products with Actial in an increasing number of territories
will continue throughout this financial year.
7. Stability studies:
a. SlimBiome(R) Medical has received regulatory approval for 36 months shelf life
b. CholBiome and CholBiome(X3) have achieved 24 month stability
c. CholBiome(X3) has achieved stability in zone 4b (temp 30C 75%
relative humidity). This includes countries such as India, Southern
Asia, Africa, and parts of the Middle east and South America.
Long term stability studies are important as they are a
prerequisite for regulatory approval in many countries, large
corporate partners, and international retailers. OptiBiotix has at
least 24 months stability for its SlimBiome(R) and LP(LDL) (R)
products. This allows OptiBiotix and its partners to place larger
orders reducing the cost of goods and increasing margins. The lower
cost of goods and zone 4b stability studies are important for
product launches in India, Southern Asia, and many middle Eastern
and South American markets and is a precursor for orders with our
existing partners in these regions.
8. Turnkey solutions: As OptiBiotix focuses on selling more
product than ingredients it has developed an extensive range of
marketing flyers, scientific publications, videos, graphic, case
studies and a science data package to support its partners. It also
provides turnkey websites which link directly to payment solutions
in multiple languages. These include: https://slimbiome.ph/;
https://www.slimbiome.ph/id ; https://slimbiome.com.au/;
http://slimbiome.de/; https://gofigure.pl/; https://lpldl.com/. The
overall aim is to make it as easy as possible for partners to
market and sell OptiBiotix's final products in different
territories around the world.
9. SweetBiotix (R): There has been good progress of the
Company's manufacturing partner who are in the process of
manufacturing an initial run of two metric tonnes of
SweetBiotix(R). This will be the first industrial scale manufacture
of SweetBiotix(R) products. The manufacturing scale up of
SweetBiotix(R) is being paralleled by the release of a number of
independent peer reviewed publications demonstrating prebiotic
activity and superior taste profile and open innovation application
development with global partners.
10. LP(LDL) (R) drug biotherapeutic : The Company has employed
Christopher Nother on a part time consultancy basis to explore the
use of LP(LDL) (R) in pharma, either as an 'over the counter' (OTC)
product, or a drug biotherapeutic in markets outside the USA.
LP(LDL) (R) has already received an investigational New Drug
Approval with Seed Health for a Phase II pharma clinical study. The
Company will shortly be publishing placebo controlled human studies
which show LP(LDL) (R) can achieve similar reductions in total
cholesterol and LDL (bad cholesterol) to statins, without any side
effects. Early discussions suggest that ProBiotix's existing humans
studies provide safety, tolerance, and efficacy comparable to that
typically seen in a Phase II pharma study. If this is confirmed the
risk, timeline, and costs to develop LP(LDL) (R) as a drug
biotherapeutic is substantially reduced. Chris is currently
assessing the costs and timelines to develop LP(LDL) (R) as a drug
biotherapeutic and the potential to create a biotherapeutic drug
division or separate Limited company to fully exploit the
opportunity and potential for significant upside.
Stephen O'Hara, CEO of OptiBiotix Health plc c o m mented: " The
Company is in a pivotal position in reporting profitability within
its divisions from early sales of our first generation products
whilst building the scientific and clinical evidence base to
de-risk our highly innovative second generation products. These
offer the potential to open significantly larger market
opportunities whilst having a low overhead sustainable business
model from which to rapidly scale. Strong progress in Q1 2021 with
manufacturing scale up of SweetBiotix, development of LP(LDL) (R)
as a drug biotherapeutic, product line and territory extensions of
existing products with corporate and retail partners, coupled with
progress in the Indian and Asian markets, puts the Company in a
strong position for future growth in this exciting area of
healthcare."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDSFFFWMEFSELD
(END) Dow Jones Newswires
March 17, 2021 03:00 ET (07:00 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Apr 2023 a Apr 2024